Cassava Sciences is an American pharmaceutical company based in Austin, Texas. The company was developing simufilam (previously known as PTI-125 and sumifilam), an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| SAVA | CASSAVA SCIENCES INC | 2026-03-10 18:59:45 | 2.34 | -0.04 | -1.52 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SAVA | 0001069530 | CASSAVA SCIENCES INC | US14817C1071 | — | 911911336 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 6801 N CAPITAL OF TEXAS HIGHWAY | AUSTIN | TX | 78731 | UNITED STATES | US | 512-501-2444 | 6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX, 78731 | 6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX, 78731 | CASSAVA SCIENCES INC | Pharmaceuticals | 1998 | — | — | https://www.cassavasciences.com | 87,000,000 | 48,307,896 | 48,307,896 | Cassava Sciences is an American pharmaceutical company based in Austin, Texas. The company was developing simufilam (previously known as PTI-125 and sumifilam), an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials. | 2026-03-12 20:12:21 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 87,000,000 | -471,000,000 | -84.4086 | 48,307,896 | 0 | 0 |
| 2024 | 558,000,000 | -409,000,000 | -42.2958 | 48,307,896 | 5,082,685 | 11.7586 |
| 2023 | 967,000,000 | -133,000,000 | -12.0909 | 43,225,211 | 1,489,654 | 3.5693 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| James W. Kupiec | Chief Medical Officer | 2024 | 449,000 | 50,000 | 0 | — | 0 | 3,306,128 |
| Eric J. Schoen | Chief Financial Officer | 2024 | 475,000 | 250,000 | 0 | — | 0 | 3,850,772 |
| Richard J. Barry | Chief Executive Officer, President | 2024 | 309,375 | 0 | 0 | — | 10,000 | 16,729,425 |
| Remi Barbier | Chief Executive Officer, President | 2024 | 867,708 | 500,000 | 0 | — | 1,255,950 | 3,685,803 |
| Eric J. Schoen | Chief Financial Officer | 2023 | 460,000 | 0 | 0 | — | 0 | 2,992,825 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 17 |
| 2024 | 30 |
| 2023 | 29 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | — | — | — |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 26,590,000 | 69,637,000 | 89,423,000 |
| General And Administrative Expenses | 68,800,000 | 71,809,000 | 16,534,000 |
| Operating Expenses | 95,390,000 | 141,446,000 | 105,957,000 |
| Operating Income | -95,390,000 | -141,446,000 | -105,957,000 |
| Net Income | -90,973,000 | -24,342,000 | -97,217,000 |
| Earnings Per Share Basic | -1.88 | -0.53 | -2.32 |
| Earnings Per Share Diluted | -1.88 | -1.46 | — |
| Weighted Average Shares Outstanding Basic | 48,297,000 | 46,329,000 | 41,932,000 |
| Weighted Average Shares Outstanding Diluted | 48,297,000 | 46,604,000 | — |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 95,502,000 | 128,574,000 | 121,136,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | — | — | — |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 64,000 | 38,000 | 287,000 |
| Total Assets Current | 97,709,000 | 136,532,000 | 129,633,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 20,646,000 | 20,964,000 | 21,854,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 20,646,000 | 21,001,000 | 22,030,000 |
| Total Assets | 118,355,000 | 157,533,000 | 151,663,000 |
| Accounts Payable | 41,647,000 | 7,654,000 | 10,573,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 198,000 | 299,000 | 385,000 |
| Total Liabilities Current | 43,834,000 | 11,750,000 | 14,195,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 118,000 | 79,000 | 0 |
| Total Liabilities Non Current | 118,000 | 79,000 | 0 |
| Total Liabilities | 43,952,000 | 11,829,000 | 14,195,000 |
| Common Stock | 48,000 | 48,000 | 42,000 |
| Retained Earnings | -496,084,000 | -405,111,000 | -380,769,000 |
| Accumulated Other Comprehensive Income | — | — | — |
| Total Shareholders Equity | 74,403,000 | 145,704,000 | 137,468,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 903,000 | 952,000 | 1,084,000 |
| Share Based Compensation Expense | 19,582,000 | 16,291,000 | 4,586,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | — | — | — |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 33,993,000 | -2,919,000 | 6,896,000 |
| Change In Other Liabilities | -62,000 | -7,000 | -304,000 |
| Cash From Operating Activities | -32,252,000 | -116,929,000 | -82,025,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 581,000 | 103,000 | 414,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -581,000 | -103,000 | -414,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | 0 | 0 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -239,000 | 124,470,000 | 2,560,000 |
| Change In Cash | -33,072,000 | 7,438,000 | -79,879,000 |
| Cash At End Of Period | 95,502,000 | 128,574,000 | 121,136,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | — | — | — |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -1.88 | -0.53 | -2.32 |
| Price To Earnings Ratio | -1.0532 | -4.4528 | -9.7026 |
| Earnings Growth Rate | 254.717 | -77.1552 | — |
| Price Earnings To Growth Ratio | -0.0041 | 0.0577 | — |
| Book Value Per Share | 1.5405 | 3.145 | 3.2784 |
| Price To Book Ratio | 1.2853 | 0.7504 | 6.8662 |
| Ebitda | -90,070,000 | -23,390,000 | -96,133,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 585,000 | 62,000 | 74,000 |
| Free Cash Flow | -32,837,000 | -116,991,000 | -82,099,000 |
| Return On Equity | -1.2227 | -0.1671 | -0.7072 |
| One Year Beta | 0.944 | 1.4328 | 1.2385 |
| Three Year Beta | 1.113 | 1.1228 | 1.4694 |
| Five Year Beta | 1.3196 | 1.322 | 1.2554 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Anderson Robert Eugene Jr | Director | 2025-11-24 | 8,600 | A | 8,600 |
| Barry Richard | Director, President & CEO | 2025-11-20 | 150,000 | A | 938,060 |
| Barry Richard | Director, President & CEO | 2025-11-19 | 73,385 | A | 788,060 |
| Bir Dawn Carter | Director | 2025-10-21 | 53,000 | A | 53,000 |
| Cook Robert Christopher | Chief Operating & Legal Office | 2025-09-30 | 13,725 | A | 13,725 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Christopher L. Jacobs | 2023-01-20 | NY27 | Purchase | 2022-12-12 | — | $1,001 - $15,000 |
| Christopher L. Jacobs | 2022-12-12 | NY27 | Sale | 2022-11-08 | — | $1,001 - $15,000 |
| Christopher L. Jacobs | 2022-11-16 | NY27 | Purchase | 2022-10-12 | — | $1,001 - $15,000 |
| Christopher L. Jacobs | 2022-09-09 | NY27 | Sale | 2022-07-18 | — | $1,001 - $15,000 |
| Christopher L. Jacobs | 2022-07-28 | NY27 | Purchase | 2022-06-21 | — | $15,001 - $50,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | 2025-12-31 | 65,318 | 32,989 | 1.98 |
| HSBC HOLDINGS PLC | 2025-12-31 | 19,701 | 10,000 | 1.9701 |
| Rockefeller Capital Management L.P. | 2025-12-31 | 10 | 5 | 2 |
| Caitong International Asset Management Co., Ltd | 2025-12-31 | 26,940 | 13,606 | 1.98 |
| Virtu Financial LLC | 2025-12-31 | 97,000 | 48,832 | 1.9864 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| iSHARES TRUST | 2026-01-31 | iShares Neuroscience and Healthcare ETF | IBRN | 2,457 | 4,889.43 | 0.1 |
| SCHWAB CAPITAL TRUST | 2026-01-31 | Schwab Total Stock Market Index Fund | SWTSX | 25,000 | 49,750 | 0.0001 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 2025-12-31 | Institutional Plus Shares | VITPX | 20,730 | 41,045.4 | 0.0001 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 2025-12-31 | Institutional Shares | VITNX | 20,730 | 41,045.4 | 0.0001 |
| VANGUARD INDEX FUNDS | 2025-12-31 | Institutional Select Shares | VSTSX | 1,365,843 | 2,704,369.14 | 0.0001 |